NASDAQ:OKUR OnKure Therapeutics Q3 2026 Earnings Results & Report $2.87 -0.14 (-4.52%) As of 01:12 PM Eastern This is a fair market value price provided by Massive. Learn more. OnKure Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$0.36 versus the -$0.4067 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 4, 2026TimeAfter Market ClosesConference Call7:00 AM ET OnKure Therapeutics EPS ResultsActual EPS-$0.36Consensus EPS -$0.4067Beat/MissBeat by +$0.0467One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersOnKure Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$167 thousandBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) OnKure Therapeutics Q3 2026 Earnings FAQ Did OnKure Therapeutics beat earnings estimates for Q3 2026? OnKure Therapeutics (NASDAQ:OKUR) reported earnings of -$0.36 per share for Q3 2026, beating the consensus estimate of -$0.4067. The report was announced on Wednesday, November 4, 2026. OnKure Therapeutics Earnings HeadlinesOnKure Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMOnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business HighlightsNovember 4, 2026 | globenewswire.comTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.November 13 at 1:00 AM | Traders Agency (Ad)Onkure Therapeutics Inc (OKUR)September 25, 2026 | investing.comOnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare ConferenceAugust 31, 2026 | globenewswire.comOnKure Therapeutics Inc. - Ordinary Shares - Class AAugust 19, 2026 | money.usnews.comSee More OnKure Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OnKure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OnKure Therapeutics and other key companies, straight to your email. Email Address About OnKure TherapeuticsOnKure Therapeutics (NASDAQ:OKUR) is a clinical-stage biotechnology company focused on developing precision medicines for cancer. Its research centers on targeted therapies designed to address molecular changes that can drive tumor growth. The company’s pipeline includes OKI-219, an investigational small-molecule therapy designed to selectively inhibit a mutant form of PI3Kα. OnKure has also worked on drug candidates targeting epigenetic mechanisms involved in cancer, reflecting its broader focus on developing treatments against specific cancer-related targets. OnKure is based in the United States and advances its programs through clinical development. Its medicines remain investigational and have not been established as safe or effective for any use.View OnKure Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
